Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Published 18/10/2023, 13:18
© Reuters.  Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Benzinga - by Lisa Levin, Benzinga Editor.

Gainers

  • Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.
  • Shift Technologies, Inc. (NASDAQ: SFT) shares rose 74.4% to $0.1878 in pre-market trading. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection.
  • Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares gained 45% to $2.45 in pre-market trading after gaining around 4% on Tuesday.
  • RVL Pharmaceuticals plc (NASDAQ: RVLP) shares climbed 41.2% to $0.0720 in pre-market trading after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12, the company received a delisting notice from the Listing Qualifications Department of Nasdaq Stock Market LLC.
  • Intelligent Bio Solutions Inc. (NASDAQ: INBS) rose 28.6% to $0.3912 in pre-market trading.
  • Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) shares rose 14.4% to $0.3498 in pre-market trading after jumping 15% on Tuesday.
  • Advent Technologies Holdings, Inc. (NASDAQ: ADN) gained 14.3% to $0.4799 in pre-market trading.
  • Micromobility.com Inc. (NASDAQ: MCOM) shares rose 12.8% to $0.0466 in pre-market trading after surging 15% on Tuesday.
  • Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 11.4% to $11.95 in pre-market trading. Viking Therapeutics presented new data from the Phase 1 clinical trial of dual GLP-1/GIP receptor agonist VK2735 in an oral presentation at ObesityWeek 2023.
  • Talaris Therapeutics, Inc. (NASDAQ: TALS) shares jumped 8.2% to $3.05 in pre-market trading after the company reported stockholder approval of merger with Tourmaline Bio and announced a 1-for-10 reverse stock split of common stock.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Losers
  • NuZee, Inc. (NASDAQ: NUZE) dipped 30.8% to $3.60 in pre-market trading after announcing a proposed public offering of common stock.
  • Nuvve Holding Corp. (NASDAQ: NVVE) shares fell 13.4% to $0.2270 in pre-market trading after dipping 33% on Tuesday.
  • SciSparc Ltd. (NASDAQ: SPRC) shares fell 12.5% to $5.52 in pre-market trading, after jumping 123% on Tuesday. The company recently announced the closing of a $5 million private placement and regained compliance with the Nasdaq minimum bid price rule.
  • Notable Labs, Inc. (NASDAQ: NTBL) fell 12.5% to $3.93 in pre-market. JMP Securities initiated coverage on Notable Labs with a Market Outperform rating and announced a price target of $13.
  • BIO-key International, Inc. (NASDAQ: BKYI) shares fell 11.5% to $0.3022 in pre-market trading after declining 34% on Tuesday. BIO-Key International filed for an offering of units of up to $10 million.
  • Ucommune International Ltd (NASDAQ: UK) shares fell 9.1% to $0.3090 in pre-market trading after declining 8% on Tuesday. Ucommune International said that an extraordinary general meeting of the Company will be held on Nov. 29, 2023.
  • China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares fell 8.5% to $2.92 in pre-market trading after gaining over 10% on Tuesday. China SXT Pharmaceuticals recently announced a 1-for-25 reverse stock split.
  • Blue Star Foods Corp. (NASDAQ: BSFC) shares fell 6.8% to $0.1842 in pre-market trading, after gaining over 8% on Tuesday.
  • Bio-Path Holdings, Inc. (NASDAQ: BPTH) fell 6.5% to $0.5802 in pre-market trading after declining around 9% on Tuesday.
  • Tempest Therapeutics, Inc. (NASDAQ: TPST) fell 5.6% to $6.77 in pre-market trading. Last Wednesday, TPST shares soared nearly 4000% after the company announced results from its ongoing Phase 1B/2 study of the company's TPST-1120 combination, which showed clinical superiority to existing treatments.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Fear & Greed Index Remains In 'Fear' Zone As Investors Assess Earnings Reports

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.